二甲双胍+钠-葡萄糖协同转运蛋白2抑制剂：一片药中的促健康生活方式模拟物？
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
作者信息
Kalra Sanjay, Jacob Jubbin, Baruah Manash P
机构信息
Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
Department of Endocrinology, Christian Medical College, Ludhiana, Punjab, India.
出版信息
Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):164-166. doi: 10.4103/ijem.IJEM_266_17.
Abstract
Salutogenesis is an accepted approach for chronic disease management. Calorie restriction and exercise are two evidence based salutogenic interventions in diabetes treatment. Calorie restriction mimetics and exercise mimetics may be used as pharmacological tools to help manage diabetes in a sulutogenic manner. This article discusses the biochemical basis and pharmacology of metformin and sodium glucose cotransporter 2 inhibitors. It describes how a combination of these drugs can be used as a calories restriction and exercise mimetic, to help improve diabetes control.
摘要
健康生成学是一种被认可的慢性病管理方法。热量限制和运动是糖尿病治疗中两种基于证据的健康生成干预措施。热量限制模拟物和运动模拟物可用作药理学工具，以健康生成的方式帮助管理糖尿病。本文讨论了二甲双胍和钠-葡萄糖协同转运蛋白2抑制剂的生化基础和药理学。它描述了如何将这些药物联合使用，作为热量限制和运动模拟物，以帮助改善糖尿病控制。
相似文献
1
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?二甲双胍+钠-葡萄糖协同转运蛋白2抑制剂：一片药中的促健康生活方式模拟物？
Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):164-166. doi: 10.4103/ijem.IJEM_266_17.
2
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
3
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的早期应用的理由。
Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23.
4
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.在阿拉伯联合酋长国2型糖尿病患者中，评估卡格列净与达格列净和恩格列净作为二甲双胍附加治疗时的血糖反应成本。
Curr Med Res Opin. 2017 Jun;33(6):1155-1163. doi: 10.1080/03007995.2017.1310091. Epub 2017 Apr 28.
5
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.在英国2型糖尿病患者中使用钠-葡萄糖协同转运蛋白2抑制剂实现血糖目标的成本
Diabetes Ther. 2017 Oct;8(5):1175-1185. doi: 10.1007/s13300-017-0312-1. Epub 2017 Sep 25.
6
Newer antidiabetic drugs and calorie restriction mimicry.新型抗糖尿病药物与热量限制模拟物。
Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):142-6. doi: 10.4103/2230-8210.172242.
7
Can we go beyond surrogates?我们能否超越代理人？
J Diabetes. 2017 Nov;9(11):976-977. doi: 10.1111/1753-0407.12583.
8
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病治疗中的作用
Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16.
9
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.钠-葡萄糖协同转运蛋白2抑制剂在血糖控制之外的益处——聚焦代谢、心血管和肾脏结局
Curr Diabetes Rev. 2018;14(6):509-517. doi: 10.2174/1573399813666170816142351.
10
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.恩格列净与卡格列净、达格列净或标准治疗方案相比在2型糖尿病合并已确诊心血管疾病患者中的成本效益
BMJ Open Diabetes Res Care. 2021 May;9(1). doi: 10.1136/bmjdrc-2020-001313.
本文引用的文献
1
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.恩格列净通过促进脂肪利用和棕色化以及通过极化 M2 巨噬细胞来减轻炎症和胰岛素抵抗，从而抑制 SGLT2。在饮食诱导肥胖的小鼠中。
EBioMedicine. 2017 Jun;20:137-149. doi: 10.1016/j.ebiom.2017.05.028. Epub 2017 May 26.
2
Classification of non-insulin glucose lowering drugs.非胰岛素类降糖药物的分类
J Pak Med Assoc. 2016 Nov;66(11):1497-1498.
3
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.钠-葡萄糖协同转运蛋白2抑制作用与健康益处：罗宾汉效应。
Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):725-729. doi: 10.4103/2230-8210.183826.
4
Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy.基于单磷酸腺苷激活蛋白激酶的糖尿病药物治疗分类
J Postgrad Med. 2017 Apr-Jun;63(2):114-121. doi: 10.4103/0022-3859.191007.
5
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：现状与未来展望
Eur J Pharm Sci. 2016 Oct 10;93:244-52. doi: 10.1016/j.ejps.2016.08.025. Epub 2016 Aug 12.
6
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.钠/葡萄糖协同转运蛋白抑制剂卡格列净通过抑制线粒体功能和增加细胞内AMP水平来激活AMPK。
Diabetes. 2016 Sep;65(9):2784-94. doi: 10.2337/db16-0058. Epub 2016 Jul 5.
7
Newer antidiabetic drugs and calorie restriction mimicry.新型抗糖尿病药物与热量限制模拟物。
Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):142-6. doi: 10.4103/2230-8210.172242.
8
Exercise: the lifelong supplement for healthy ageing and slowing down the onset of frailty.运动：健康老龄化和延缓身体虚弱 onset 的终身补充剂。
注：这里“onset”直接保留英文未准确翻译，可改为“运动：健康老龄化和延缓身体虚弱发生的终身补充剂。” 原英文表述中onset单独使用表意不太明确，推测完整意思可能是“延缓身体虚弱的发生” 。
J Physiol. 2016 Apr 15;594(8):1989-99. doi: 10.1113/JP270536.
9
Caloric restriction and exercise "mimetics'': Ready for prime time?热量限制与运动“模拟物”：准备好迎接黄金时代了吗？
Pharmacol Res. 2016 Jan;103:158-66. doi: 10.1016/j.phrs.2015.11.009. Epub 2015 Dec 2.
10
Calorie restriction as an intervention in ageing.热量限制作为一种延缓衰老的干预措施。
J Physiol. 2016 Apr 15;594(8):2043-60. doi: 10.1113/JP270543. Epub 2016 Jan 3.
Zotero 插件